SCHEMBL118201

SCHEMBL118201

CCOC(=O)c1cn2cccc(N)c2n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.56
KDM4E B2RXH2 3/20 0.56
HPGD P15428 1/20 0.56
POLB P06746 2/20 0.53
CYP1A2 P05177 1/20 0.49
GAA P10253 1/20 0.48
MAPK1 P28482 1/20 0.47
HSD17B10 Q99714 1/20 0.47
GABRA2 P47869 5/20 0.46
GABRB2 P47870 5/20 0.46
SMN1; SMN2 Q16637 3/20 0.44
RAB9A P51151 3/20 0.44
MAPT P10636 2/20 0.44
DHFR P00374 1/20 0.43
ADORA2A P29274 1/20 0.43
NPC1 O15118 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
HTR2A P28223 1/20 0.42
HTR2C P28335 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL102433 0.86 KDM4E (0.59) ALDH1A1KDM4EHPGDPOLBCYP1A2
SCHEMBL9090050 0.85 KDM4E (0.58) ALDH1A1KDM4EHPGDPOLBCYP1A2
SCHEMBL117700 0.85 KDM4E (0.58) ALDH1A1KDM4EHPGDPOLBCYP1A2
SCHEMBL7274828 0.85 KDM4E (0.58) ALDH1A1KDM4EHPGDPOLBCYP1A2
SCHEMBL118914 0.83 KDM4E (0.55) ALDH1A1KDM4EHPGDPOLBCYP1A2
SCHEMBL8190856 0.83 KDM4E (0.55) ALDH1A1KDM4EHPGDPOLBCYP1A2
SCHEMBL1202722 0.83 KDM4E (0.55) ALDH1A1KDM4EHPGDPOLBCYP1A2
SCHEMBL29469813 0.82 KDM4E (0.52) ALDH1A1KDM4EHPGDPOLBCYP1A2
SCHEMBL24857536 0.82 KDM4E (0.54) ALDH1A1KDM4EHPGDPOLBCYP1A2
SCHEMBL8607273 0.82 KDM4E (0.54) ALDH1A1KDM4EHPGDPOLBCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120101093-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS HIGH POINT PHARMACEUTICALS, LLC (US) 2012-04-26 US disclosed
EP-2424866-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS -SECRETASE INHIBITORS High Point Pharmaceuticals, LLC (US) 2012-03-07 EP disclosed
WO-2010126745-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS β-SECRETASE INHIBITORS HIGH POINT PHARMACEUTICALS, LLC (US) 2010-11-04 WO disclosed
EP-0370381-B1 2(1H)-quinolinone compounds, processes for the preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO (JP) 1995-05-10 EP disclosed
US-4988698-A Cardiovascular disorders, hypotensive agents FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-01-29 US disclosed
EP-0370381-A2 2(1H)-quinolinone compounds, processes for the preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1990-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101093-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS BACE1, BACE2, APP ALDH1A1 2155/4885KDM4E 2967/4885HPGD 2417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.